Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P; Phoenix and Tucson Gastroenterologist Networks. Alberts DS, et al. Among authors: clouser m. J Natl Cancer Inst. 2005 Jun 1;97(11):846-53. doi: 10.1093/jnci/dji144. J Natl Cancer Inst. 2005. PMID: 15928305 Clinical Trial.
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS. Chambers SK, et al. Among authors: clouser mc. Clin Cancer Res. 2010 Nov 1;16(21):5320-8. doi: 10.1158/1078-0432.CCR-10-0974. Clin Cancer Res. 2010. PMID: 21041183 Free PMC article. Clinical Trial.
Biomarker targets and novel therapeutics.
Clouser M, Hess LM, Chambers SK. Clouser M, et al. Cancer Treat Res. 2009;149:85-105. doi: 10.1007/978-0-387-98094-2_4. Cancer Treat Res. 2009. PMID: 19763432 Review. No abstract available.
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M; Southwest Oncology Group. Alberts DS, et al. Among authors: clouser mc. Gynecol Oncol. 2008 Jan;108(1):90-4. doi: 10.1016/j.ygyno.2007.08.075. Epub 2007 Oct 18. Gynecol Oncol. 2008. PMID: 17949799 Free PMC article. Clinical Trial.
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M; GRACES Clinical Trial Consortium. Alberts DS, et al. Among authors: clouser mc. Gynecol Oncol. 2008 May;109(2):174-81. doi: 10.1016/j.ygyno.2008.01.005. Epub 2008 Mar 7. Gynecol Oncol. 2008. PMID: 18314182 Clinical Trial.
38 results